Dexcom, Inc. Promotes Jereme Sylvain to EVP, COO & CFO

What Happened

• Dexcom announced that on Sept. 10, 2026 its Board appointed Jereme Sylvain (previously EVP, CFO) to the combined role of Executive Vice President, Chief Operating Officer and Chief Financial Officer, effective Sept. 14, 2026.
• On Sept. 11, 2026 Mr. Sylvain signed an offer letter setting an annual base salary of $767,000 and an annual target bonus equal to 75% of base salary. He remains eligible for annual equity awards under the company’s Amended and Restated 2015 Equity Incentive Plan and for participation in the company’s Severance & Change in Control Plan and other employee benefit plans.

Key Details

• Appointment effective date: September 14, 2026.
• Base salary: $767,000 per year; target annual bonus: 75% of base salary.
• Equity and benefit eligibility: continues to participate in Dexcom’s 2015 Equity Incentive Plan and executive severance/change‑in‑control plan.
• Company disclosed no related‑party arrangements, no family relationships with other directors/executive officers, and no reportable material transactions involving Mr. Sylvain.

Why It Matters

• The promotion consolidates Dexcom’s finance and operations leadership under a single executive, which may affect execution of strategy and operational oversight.
• Compensation details give investors clarity on the cash and incentive structure for a key executive; the company will file the full offer letter as an exhibit to its next Form 10‑Q for the quarter ending Sept. 30, 2026 for additional specifics.
• The filing is procedural and factual (appointment, pay, continued equity/severance eligibility) and does not disclose changes to guidance, financial results, or new contractual severance terms beyond continued plan participation.